Armistice Capital’s HCW Biologics HCWB Stock Holding History

Armistice Capital’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,030	Closed	-$291K	–	359
2025 Q4	$291K	Buy	+50,030	New	+$850K	﹤0.01%	296
2025 Q1	–	Sell	-8,432	Closed	-$903K	–	256
2024 Q4	$903K	Buy	+8,432	New	+$984K	0.01%	170

Other funds holding HCWB

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital's HCWB Position: Q1 2026 in Review

Armistice Capital sold out of HCW Biologics (HCWB) in Q1 2026, closing a stake of 50,030 shares — an estimated $291K sold.

Armistice Capital first reported a position in HCWB in Q4 2024 and held it in 2 quarters. The position peaked at $903K in Q4 2024. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

Armistice Capital reported no remaining HCW Biologics position as of Q1 2026 after selling out during the quarter.
Armistice Capital sold 50,030 HCW Biologics shares in Q1 2026, an estimated $291K.
Armistice Capital first reported a position in HCW Biologics in Q4 2024 and held it in 2 quarters.
Armistice Capital's HCW Biologics position peaked at $903K in Q4 2024.
13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.